<DOC>
	<DOCNO>NCT02409095</DOCNO>
	<brief_summary>This study plan determine compare immunogenicity reactogenicity DTP-HB-Hib vaccine SIIL deliver either disposable-Syringe Jet Injector ( DSJI ) disposable-syringe needle total 340 Indian infant age 6 8 week time enrollment . It provide information aid manager , device regulatory control official , immunization program , clinician make decision safe clinical practice standard .</brief_summary>
	<brief_title>Study Comparing DTP-HB-Hib Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants</brief_title>
	<detailed_description>This randomize , observer blind , non-inferior , parallel group , multi-centre clinical study determine compare immunogenicity reactogenicity DTP-HB-Hib vaccine Serum Institute India Ltd. deliver either disposable-Syringe Jet Injector ( DSJI ) disposable-syringe needle total 340 Indian infant . Sera sample analyze ELISA seroconversion / seropositivity individual component vaccine i.e . Diphtheria , Tetanus , Pertussis , Hepatitis B ( HBsAg ) Hemophilus Influenza B 28 day administration third dose vaccine .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Normal healthy infant age 68 week time first vaccination . 2 . Born normal gestation period ( 3642 week ) . 3 . Parents subject willing give write informed consent . 4 . Parents willing comply study protocol . 5 . Free obvious health problem establish medical history screen evaluation include clinical examination . 6 . The participant resident study area 1 . Infant subject participate clinical trial plan participation another clinical trial present trial period . 2 . Infant congenital acquire immunodeficiency , malignancy receive immunosuppressive therapy systemic corticosteroid therapy period â‰¥ 1 week . 3 . Infant history allergy systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . 4 . Infant chronic illness include hepatic , renal , respiratory , CVS , endocrine neurological illness . 5 . Infants receive blood bloodderived product past . 6 . History diphtheria , tetanus , pertussis , hepatitis B Haemophilus influenzae type b ( confirm either clinically , serologically microbiologically ) . 7 . Previous history vaccination diphtheria , tetanus , pertussis Hib . 8 . Known history bleed disorder contraindicate intramuscular vaccination . 9 . History neurological disorder history seizure ( febrile afebrile ) , encephalopathy , encephalitis , hypotonichyporesponsive episode . 10 . History febrile illness time inclusion temporary exclusion criterion . 11 . Acute chronic , clinically significant pulmonary , endocrine , autoimmune , cardiovascular , metabolic , hepatic renal functional abnormality , determine medical history , physical examination test , opinion investigator , might interfere study objective 12 . Infant condition , , opinion investigator would jeopardize safety right infant participate study make unlikely subject could complete protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>